

Allokering til endokrin behandling iht. Q-score

Maj-Britt Jensen
DBCG's sekretariat

Excess mortality in postmenopausal high-risk ER+ breast cancer patients

ACTA 2014

C kohorte, ET

1996-2004

0, 1-3, 4+ pos LN

Post ER+

N=6529

	N	SMR	
Q1	1586	0.96 (0.86;1.06)	ET
Q2	1587	1.58 (1.43;1.75)	KT+ET
Q3	1587	2.43 (2.21;2.61)	KT+ET
Q4	1587	5.86 (5.46;6.29)	KT+ET
?	182		


Post, ER 10+%, 0-3 pos LN, Her2N

	2000-03		SMR
Q1	906	36%	0.95 (0.82;1.09)
Q2	782	31%	1.51 (1.28;1.78)
Q3	590	24%	2.23 (1.85;2.69)
Q4	213	9%	4.42 (3.40;5.75)
Total	2491		


Post, ER 10+%, 0-3 pos LN, Her2N

	2000-03		2015	
Q1	906	36%	1219	72%
Q2	782	31%	301	18%
Q3	590	24%	141	8%
Q4	213	9%	31	2%
Total	2491		1692	


Antal patienter pr år 1996 - 2015




Antal patienter i protokol pr år 1996 - 2015



Antal patienter i protokol pr år 1996 - 2015




Antal patienter i protokol pr år 1996 - 2015




B: KT + ET

C: ET


Antal patienter i protokol B (KT+ET), C (ET)



Antal postmenopausale patienter i protokol B,C



Antal postmenopausale HER2N, ER10+% patienter i protokol B,C



Post, ≥50, ER 10+%, HER2N, Højrisiko

2012	Q1	Q2-Q4	Total	
B	56	191	247	16%
C	1050	211	1261	84%
Total	1106	402	1508	
	73%	27%		

Post, ≥50, ER 10+%, HER2N, Højrisko

2012	Q1	Q2-Q4	Total	
B	56	191	247	16%
C	1050	211	1261	84%
Total	1106	402	1508	
	73%	27%		

Post, ≥50, ER 10+%, HER2N, Højrisko

2012	Q1	Q2-Q4	Total
B	56	191	247
C	1050	211	1261
Total	1106	402	1508
	73%	27%	

2015	Q1	Q2-Q4
	1219	473
B		473
C	1219	
	72%	28%